>>Any one following this company and the enabling technologies they have developed and licensed to Applied Biosystems and others?>>
The Street seems to disagree with EBIO's contention that its recent acquisition will accelerate the path to profitability. Alan Auerbach of van Kasper, the only analyst on this stock, increased his estimates of EBIO's 2001 losses dramatically. I assume because of this purchase, but we know what assumptions do.
I believe Peter Suzman owns some of this. I have a question for you, Peter. EBIO is paying $3 million cash for this outfit. Doesn't seem like it deserves the slamming it got, unless the Street believes the buy will be intially negative, in which case the credibility of the CEO is not looking good. Since he said it would help. Comments?